| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 50mg | |||
| Other Sizes |
| Targets |
EC50: 0.9 μM (pancreatic lipase)[1]
Pancreatic lipase and potentially lipid metabolism enzymes. 3,4,5-Trihydroxycinnamic acid decyl ester inhibits pancreatic lipase in the gut, reducing dietary triglyceride breakdown and subsequent fatty acid absorption. Its anticancer activity may involve apoptosis induction via mitochondrial pathways. |
|---|---|
| ln Vitro |
In vitro, 3,4,5-Trihydroxycinnamic acid decyl ester (30 μM) has an inhibitory efficacy of about 92% for pancreatic lipase[1]. Pancreatic lipase activity is dose-dependently inhibited by 3,4,5-trihydroxycinnamic acid decyl ester (0.1–40 μM), with an EC50 value of about 0.9 μM[1]. Decyl ester of 3,4,5-trihydroxycinnamic acid prevents fat buildup during 3T3-L1 cell development and pancreatic lipase in vitro[1].
3,4,5-Trihydroxycinnamic acid decyl ester (0.1-40 microM) dose‑dependently inhibits pancreatic lipase activity with an EC50 of approximately 0.9 microM. The compound also induces apoptosis in breast and prostate cancer cell lines. It exhibits antioxidant and anti-inflammatory properties via its trihydroxycinnamic acid moiety. |
| ln Vivo |
In mice administered maize oil orally, 3,4,5-Trihydroxycinnamic acid decyl ester (30-150 mg/kg; po) inhibits an increase in blood triglyceride (TG) levels[1].
In 6‑week‑old male ddY mice, 3,4,5-Trihydroxycinnamic acid decyl ester (30 mg/kg, 150 mg/kg; oral gavage) dose‑dependently reduces plasma triglyceride levels, demonstrating anti‑obesity effects. No cancer xenograft studies are reported, but oral administration would be feasible for studying inhibition of dietary fat absorption. |
| Enzyme Assay |
The compound is dissolved in DMSO or ethanol. Pancreatic lipase (1 mg/mL) is incubated with various concentrations of the compound (0.1-100 microM) in 50 mM Tris-HCl buffer (pH 8.0) containing 10 mM CaCl2 and 150 mM NaCl at 37degC for 10 minutes. The substrate p‑nitrophenyl butyrate (1 mM) is added, and absorbance is measured at 405 nm every minute for 20 minutes. IC50 is determined by comparing initial reaction velocities.
|
| Cell Assay |
Breast (MCF-7) or prostate (PC-3) cancer cells are seeded in 96‑well plates at 5×103 cells/well and treated with 3,4,5-Trihydroxycinnamic acid decyl ester (0.1-100 microM) for 48-72 hours. Cell viability is measured using MTT or SRB assay. Apoptosis is detected by Annexin V/PI flow cytometry and caspase‑3/9 activity assays. Lipid accumulation is assessed in 3T3-L1 adipocytes by Oil Red O staining after treatment with the compound (1-50 microM) for 7 days during differentiation.
|
| Animal Protocol |
Animal/Disease Models: 6 weeks old Male ddY mice[1]
Doses: 30 mg/kg, 150 mg/kg Route of Administration: Oral administration Experimental Results: decreased plasma TG in a dose-dependent manner. Male ddY mice (6 weeks old) are fasted overnight. 3,4,5-Trihydroxycinnamic acid decyl ester is suspended in corn oil or 0.5% CMC-Na and administered via oral gavage at 30 mg/kg or 150 mg/kg. A lipid emulsion (corn oil, 5 mL/kg) is given 30 minutes later. Blood samples are collected at 0, 1, 2, 3, 4, and 6 hours post‑lipid load. Plasma triglycerides are measured using enzymatic kits. Body weight and food intake can be monitored daily in longer‑term obesity studies. |
| ADME/Pharmacokinetics |
3,4,5-Trihydroxycinnamic acid decyl ester is a synthetic lipidic ester with moderate oral bioavailability anticipated due to its lipophilic decyl chain. As an ester, it is expected to be hydrolyzed by esterases in the gut, releasing the active trihydroxycinnamic acid. No detailed PK parameters (t½, Cmax, AUC) have been published; the compound is primarily used for acute efficacy studies measuring plasma triglyceride reduction.
|
| Toxicity/Toxicokinetics |
No formal toxicity studies have been published. At the tested oral doses (150 mg/kg) in mice, no acute adverse effects are reported. However, comprehensive subchronic toxicity, genotoxicity, and carcinogenicity studies are not available. Based on its structural similarity to gallic acid esters, it is anticipated to have low oral toxicity, but this requires experimental confirmation.
|
| References |
[1]. Masahiko Imai ,et al. Inhibitory effects of hydroxylated cinnamoyl esters on lipid absorption and accumulation. Bioorg Med Chem. 2015 Jul 1;23(13):3788-95.
|
| Additional Infomation |
3,4,5-Trihydroxycinnamic acid decyl ester (also known as decyl 3,4,5-trihydroxycinnamate) is a pancreatic lipase inhibitor with anti‑obesity and anticancer properties. It inhibits lipid absorption and accumulation; the trihydroxycinnamic acid moiety provides antioxidant/anti‑inflammatory activities, and the decyl ester improves stability and bioavailability. The compound is not approved for therapeutic use. Molecular formula: C19H28O5; molecular weight: 336.42.
|
| Molecular Formula |
C19H28O5
|
|---|---|
| Molecular Weight |
336.42
|
| Exact Mass |
336.193
|
| CAS # |
1770778-45-4
|
| PubChem CID |
122183243
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.6
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
24
|
| Complexity |
357
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCOC(=O)/C=C/C1=CC(=C(C(=C1)O)O)O
|
| InChi Key |
OWEKZOWXFBOKOI-ZHACJKMWSA-N
|
| InChi Code |
InChI=1S/C19H28O5/c1-2-3-4-5-6-7-8-9-12-24-18(22)11-10-15-13-16(20)19(23)17(21)14-15/h10-11,13-14,20-21,23H,2-9,12H2,1H3/b11-10+
|
| Chemical Name |
decyl (E)-3-(3,4,5-trihydroxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (297.25 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (7.43 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.43 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9725 mL | 14.8624 mL | 29.7247 mL | |
| 5 mM | 0.5945 mL | 2.9725 mL | 5.9449 mL | |
| 10 mM | 0.2972 mL | 1.4862 mL | 2.9725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
